Longeveron Inc. (NASDAQ: LGVN) received a Japan Patent Office grant for its mesenchymal stem cell (MSC) potency assay methods on January 29 2026. The patent, Japan Patent No. 2022‑563984, covers assays for MSCs derived from bone marrow, adipose tissue, peripheral blood, lung, heart, amniotic fluid, inner organs, umbilical cord, placenta, and induced pluripotent stem cells (iPSCs). The grant extends the company’s IP protection in Japan through April 20 2041, provided all annuity fees are paid, and brings Longeveron's total issued patents to 33.
The patent is a critical step for Longeveron’s flagship product, laromestrocel (Lomecel‑B), which is being advanced for hypoplastic left heart syndrome (HLHS) and other indications. Potency assays are a regulatory requirement for cell‑based therapies, and the new patent protects the proprietary methods that ensure product quality and efficacy. By securing this IP in a major global market, Longeveron strengthens its competitive moat and positions itself for potential licensing and commercial access in Japan.
Dr. Joshua M. Hare, Executive Chairman and Chief Science Officer, said the grant “reinforces our global intellectual‑property portfolio and underscores the novelty of our cell‑based therapeutic products.” He added that the new patent “expands our IP foundation to 33 issued patents, providing a robust shield for our pipeline.”
While the patent grant is a positive development, Longeveron’s financials remain modest. For the nine months ended September 30 2025, the company reported a net loss of $17.3 million on revenue of $0.8 million, and its cash and cash equivalents stood at $9.2 million. An at‑the‑market facility of up to $10.7 million is available, but the company continues to seek additional financing to support its clinical programs. The patent’s regulatory significance, however, is expected to enhance investor confidence and could improve the company’s valuation as it moves toward a U.S. Biologics License Application for HLHS.
Looking ahead, Longeveron’s pivotal Phase 2b HLHS trial is expected to deliver results in Q3 2026. Positive outcomes could trigger a U.S. FDA BLA submission and open a large pediatric market. The Japan patent also positions Longeveron to pursue licensing agreements and expand its commercial footprint in Asia, while reinforcing its strategic focus on regenerative medicine and aging‑related indications.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.